RU2647727C2 - Производные бензо[1,3]диоксина и их применение в качестве lpar5 антагонистов - Google Patents

Производные бензо[1,3]диоксина и их применение в качестве lpar5 антагонистов Download PDF

Info

Publication number
RU2647727C2
RU2647727C2 RU2014151240A RU2014151240A RU2647727C2 RU 2647727 C2 RU2647727 C2 RU 2647727C2 RU 2014151240 A RU2014151240 A RU 2014151240A RU 2014151240 A RU2014151240 A RU 2014151240A RU 2647727 C2 RU2647727 C2 RU 2647727C2
Authority
RU
Russia
Prior art keywords
dioxin
alkyl
benzo
carboxylic acid
group
Prior art date
Application number
RU2014151240A
Other languages
English (en)
Russian (ru)
Other versions
RU2014151240A (ru
Inventor
Марк Назаре
Детлеф КОЦИАН
Мартин Боссарт
Вернгард ЧЕХТИЗКИЙ
Андреас ЭФЕРС
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of RU2014151240A publication Critical patent/RU2014151240A/ru
Application granted granted Critical
Publication of RU2647727C2 publication Critical patent/RU2647727C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2014151240A 2012-05-18 2013-05-16 Производные бензо[1,3]диоксина и их применение в качестве lpar5 антагонистов RU2647727C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305553 2012-05-18
EP12305553.5 2012-05-18
PCT/EP2013/060172 WO2013171318A1 (en) 2012-05-18 2013-05-16 Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists

Publications (2)

Publication Number Publication Date
RU2014151240A RU2014151240A (ru) 2016-07-10
RU2647727C2 true RU2647727C2 (ru) 2018-03-19

Family

ID=48468297

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014151240A RU2647727C2 (ru) 2012-05-18 2013-05-16 Производные бензо[1,3]диоксина и их применение в качестве lpar5 антагонистов

Country Status (16)

Country Link
US (1) US9221784B2 (OSRAM)
EP (1) EP2850070B1 (OSRAM)
JP (1) JP6238970B2 (OSRAM)
KR (1) KR20150016304A (OSRAM)
CN (1) CN104302633B (OSRAM)
AU (1) AU2013261719B2 (OSRAM)
BR (1) BR112014028189A2 (OSRAM)
CA (1) CA2871545A1 (OSRAM)
ES (1) ES2649438T3 (OSRAM)
IL (1) IL235219A (OSRAM)
MX (1) MX354521B (OSRAM)
PL (1) PL2850070T3 (OSRAM)
RU (1) RU2647727C2 (OSRAM)
SG (1) SG11201407216YA (OSRAM)
SI (1) SI2850070T1 (OSRAM)
WO (1) WO2013171318A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200215085A1 (en) * 2017-07-19 2020-07-09 Uti Limited Partnership Method to Abate Acute Airway Hypersensitivity and Asthma Attacks
KR20250140741A (ko) 2024-03-19 2025-09-26 경북대학교 산학협력단 알룰로스를 포함하는 혈전 예방 또는 개선용 조성물 및 이의 이용

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2022579A (en) * 1978-05-03 1979-12-19 Roussel Uclaf 4h-1,3-benzodioxin-2-carboxylic acid derivatives
SU1277893A3 (ru) * 1982-05-12 1986-12-15 Империал Кемикал Индастриз,Плс (Фирма) Способ получени производных 4-фенил-1,3-диоксан-цис-5-илалкеновой кислоты или их оптически активных форм,или их физиологически приемлемых солей с основани ми
WO2005000284A2 (en) * 2003-05-20 2005-01-06 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4056540A (en) 1974-01-01 1977-11-01 Bristol-Myers Company 4-Phenyl-1,3-benzodioxans
US4056450A (en) 1975-06-30 1977-11-01 M & T Chemicals Inc. Continuous detinning system
FR2424914A2 (fr) * 1978-05-03 1979-11-30 Roussel Uclaf Nouveaux derives de (1-3) benzodioxine, un procede pour leur preparation et leur application comme medicaments
FR2704857B1 (fr) * 1993-05-07 1995-06-23 Adir Nouvelles benzodioxines substituées, leur procédé de préparation et les compositions pharmaceutiques les contenant.
CN101124226A (zh) * 2004-05-07 2008-02-13 记忆药物公司 1h-吲唑、苯并噻唑、1,2-苯并异噁唑、1,2-苯并异噻唑和色酮以及它们的制备和用途
WO2010042600A2 (en) * 2008-10-08 2010-04-15 The Uab Research Foundation Photo-activatable therapeutic agents and methods of using

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2022579A (en) * 1978-05-03 1979-12-19 Roussel Uclaf 4h-1,3-benzodioxin-2-carboxylic acid derivatives
SU1277893A3 (ru) * 1982-05-12 1986-12-15 Империал Кемикал Индастриз,Плс (Фирма) Способ получени производных 4-фенил-1,3-диоксан-цис-5-илалкеновой кислоты или их оптически активных форм,или их физиологически приемлемых солей с основани ми
WO2005000284A2 (en) * 2003-05-20 2005-01-06 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
John F.Gilmer et al. "Synthesis, hydrolysis kinetics and anti- platelet effects of isosoride mononitrate derivatives of aspirin", European J. of Pharmaceutical Seinces, 2001, v. 14, no. 3, p. 221-227. *

Also Published As

Publication number Publication date
RU2014151240A (ru) 2016-07-10
SG11201407216YA (en) 2014-12-30
CN104302633B (zh) 2016-09-07
JP6238970B2 (ja) 2017-11-29
IL235219A (en) 2017-03-30
WO2013171318A1 (en) 2013-11-21
BR112014028189A2 (pt) 2017-06-27
US9221784B2 (en) 2015-12-29
MX2014014012A (es) 2015-02-12
MX354521B (es) 2018-03-08
SI2850070T1 (en) 2018-01-31
ES2649438T3 (es) 2018-01-12
EP2850070A1 (en) 2015-03-25
EP2850070B1 (en) 2017-08-23
AU2013261719B2 (en) 2017-07-27
JP2015517515A (ja) 2015-06-22
US20150111889A1 (en) 2015-04-23
PL2850070T3 (pl) 2018-01-31
CN104302633A (zh) 2015-01-21
KR20150016304A (ko) 2015-02-11
AU2013261719A1 (en) 2014-12-18
CA2871545A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
CN116082303B (zh) 新型氧代吡啶类化合物及其中间体和应用
WO2019081573A1 (en) AROMATIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF ISCHEMIC CEREBRAL ACCIDENTS
CA3218569A1 (en) Lpa receptor antagonists and uses thereof
RU2645344C2 (ru) Производные пиразола и их применение в качестве lpar5 антагонистов
CN116262736A (zh) 新型氧代吡啶类化合物及其制备方法和用途
WO2010085968A1 (en) Toluidine sulfonamides and their use as hif-inhibitors
AU2024249981A1 (en) Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
EP2850062B1 (en) Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
JP6238970B2 (ja) ベンゾ［１，３］ジオキシン誘導体およびｌｐａｒ５アンタゴニストとしてのその使用
CN102516249A (zh) 一种抗凝血的二胺衍生物
JP2024504352A (ja) ソルチリン活性のモジュレーターとしてのピリジン誘導体
JP2021528456A (ja) Ａｓｋ１阻害剤
JP2024012577A (ja) テトラヒドロイソキノリン系誘導体、その製造方法及び用途
JP2023531097A (ja) テトラヒドロイソキノリン類誘導体の塩、その製造方法及びその医薬学的応用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200517